Celldex Therapeutics, Inc.CLDXNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank100
3Y CAGR+10.6%
5Y CAGR+79.0%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+10.6%/yr
vs +418.7%/yr prior
5Y CAGR
+79.0%/yr
Recent deceleration
Acceleration
-408.0pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
18.4x
Strong expansion
Streak
1 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 1186.40 | +419.7% |
| 2024 | 228.31 | -16.8% |
| 2023 | 274.48 | -68.7% |
| 2022 | 875.86 | +151.4% |
| 2021 | 348.40 | +439.6% |
| 2020 | 64.56 | +831.1% |
| 2019 | 6.93 | +473.0% |
| 2018 | 1.21 | -95.3% |
| 2017 | 26.00 | -44.3% |
| 2016 | 46.71 | - |